September/October 2019

The annual NASP conference has become a can't-miss event for specialty stakeholders to stay on top of rapid developments in the field.

NASP maintains a strong focus on policies affecting the national, legislative, and regulatory landscape of specialty pharmacy year round.

Blockchain, artificial intelligence, and other cutting-edge models of data management drive discussions centered on the big health data revolution.

Many industry stakeholders have been wrestling with difficult questions: How should the fair value of a drug be determined?

In today's evolving health care and reimbursement landscape, specialty pharmacies are facing pressure to adopt more efficient and cost-effective solutions.

Over the past decade, much of the health care economy has shifted from rewarding quantity (fee-for-service) to instead rewarding quality (outcome- and value-based payments).

Dupixent is the first FDA-approved medicine for adults with chronic rhinosinusitis with nasal polyposis and the only approved therapy shown to shrink nasal polyp size and improve the signs and symptoms of the associated chronic rhinosinusitis.

Debilitating and degenerative, chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease affecting 1.6 per 100,000 Americans annually.

At the recent National Association of Specialty Pharmacy Annual Meeting and Expo in Washington, DC, Jamie McConaha, PharmD, NCTTB, BCACP, CDE, associate professor of pharmacy practice at Duquesne University Mylan School of Pharmacy, and April Jones, PharmD, CSP, clinical specialty pharmacist at Vanderbilt University Medical Center, engaged specialty pharmacists in a concise but thorough presentation on psoriasis and psoriatic arthritis.

Adolescents with atopic dermatitis have unique concerns and adherence issues.

The 2019 National Association of Specialty Pharmacy (NASP) Annual Meeting and Expo began with a message of collaboration by the organization’s outgoing president, Carmine DeNardo, RPh, president and CEO of ReCept.

Fortunately, there is good news for patients with chronic conditions and who are in a high-deductible health plan.

Reform of pharmacy benefit management (PBM) practices has been an issue under much scrutiny due to a belief these entities play a significant role in exacerbating high drug costs.

During the 2019 National Association of Specialty Pharmacy Annual Meeting and Expo, Ron Lanton III, Esq, reviewed the FDA Biosimilars Action Plan, its implications for the biosimilar marketplace, recent legislation set to influence the biosimilar pathway and drug accessibility, and the future of the biosimilar market.

Specialty pharmacists a crucial role in optimizing the treatment of patients with inflammatory diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).

In an ever-changing regulatory health care landscape, specialty pharmacies must continuously ensure they are adapting to evolving industry standards.

In "2019 State of Care: Oncology/ Hematology,” during the National Association of Specialty Pharmacy 2019 Annual Meeting and Expo in Washington, DC, Joseph Barone, PharmD, BCOP, examined current standards of care for acute myeloid leukemia (AML) and multiple myeloma (MM) and identified new agents approved over the past year.

More than a year after the Trump administration’s drug pricing blueprint was released, reform has remained at the forefront of many discussions involving health care legislation.

Chronic hepatitis B virus (HBV), which affects an estimated 862,000 individuals in the United States, is caused by long-term infection with the virus and can lead to serious liver damage.

Personalized precision medical care addresses as many unique characteristics of the patient as possible.

The underlying purpose of a study presentation that won the Top Poster Award at the 2019 National Association of Specialty Pharmacy Annual Meeting and Expo in Washington, DC, was to assess whether high-touch, clinic-based specialty pharmacy services could positively affect the affordability of self- and provider-administered migraine medications for patients.

For many Americans living in today’s health care environment, cost is a dominant concern when a serious disease is diagnosed.

As a dedicated partner to the specialty pharmacy industry, Asembia provides a complete ecosystem of products and services focused on driving value in this market.

Choosing the right partner in this dynamic environment is an important decision for all stakeholders.